U.S. Consumer Finance Stock News

Why MGM’s New All-Inclusive Offer Matters for Shareholders MGM Resorts International (MGM) has rolled out a new all-inclusive vacation bundle at Luxor and Excalibur, packaging rooms, meals, entertainment, rides and parking into one upfront price for Las Vegas visitors. For investors, this product shift raises questions about how bundling could influence guest spending patterns, occupancy mix, and the balance between room revenue and on-property spending across MGM’s broader Las Vegas Strip...

On March 30, 2026, Neogen Corporation announced that Chief Legal and Administrative Officer Amy Rocklin would leave the company effective March 31, 2026, as analysts anticipated lower earnings and revenue for the quarter ending February 2026 ahead of the April 9 results release. This combination of leadership turnover in a key legal role and reduced consensus expectations has sharpened investor focus on Neogen’s governance, compliance posture, and earnings resilience. Next, we will examine...

Recent moves by Retirement Systems of Alabama and TimesSquare Capital to raise their holdings in Ollie's Bargain Outlet Holdings (OLLI) have put fresh attention on the discount retailer's store expansion plans and Ollie's Army loyalty program. See our latest analysis for Ollie's Bargain Outlet Holdings. At a share price of $95.22, Ollie's has seen a 1 day share price return of 4.36% and a 7 day share price return of 6.70%. Its 30 day and year to date share price returns are negative, while...

In early April 2026, Extreme Networks outlined its growth plans at the Morgan Stanley Technology, Media & Telecom Conference, highlighting targets for 10% revenue growth, 20% EPS growth, next‑generation 400- and 800-gigabit switches, its Platform ONE with Agentic AI, and a new German data center to address European data sovereignty. These announcements, combined with better-than-expected second-quarter results and Wolfe Research flagging the company as highly attractive to potential...

In March 2026, Crinetics Pharmaceuticals submitted a Marketing Authorization Application to Brazil’s ANVISA for PALSONIFY, an oral somatostatin receptor type 2 agonist for adult acromegaly, supported by 18 clinical trials including two Phase 3 studies that met all primary and secondary endpoints and showed favorable tolerability, biochemical control and symptom relief versus placebo. This filing extends PALSONIFY’s regulatory footprint beyond its existing US approval and recent positive CHMP...

In recent days, GLOBALFOUNDRIES Inc. announced past participation at the International Conference on Display Technology 2026 in Chongqing, China, while also disclosing new patent infringement lawsuits against Tower Semiconductor and an insider share sale by Chief Business Officer Michael James Hogan under a Rule 10b5-1 plan. At the same time, a Mubadala Investment Co. unit’s US$840 million secondary share sale, which does not raise capital for GLOBALFOUNDRIES, has sharpened attention on...

Mach Natural Resources (MNR) drew fresh attention after Wall Street Zen analysts raised their rating from buy to strong buy, citing the partnership’s energy infrastructure and production assets in the Anadarko Basin. See our latest analysis for Mach Natural Resources. The rating upgrade follows a period of strong performance, with Mach Natural Resources delivering a 90-day share price return of 25.65% and a 1-year total shareholder return of 19.64%, indicating that momentum has been building...

Leadership overhaul and fresh management lineup at Aurinia Aurinia Pharmaceuticals (AUPH) has undergone a broad leadership reset, with Kevin Tang becoming Chief Executive Officer, Michael Hearne stepping in as Chief Financial Officer, and Ryan Cole taking on the Chief Operating Officer role. These appointments follow the departure of former CEO Peter Greenleaf and several senior officers. They also bring in multiple executives with ties to Tang Capital Management, a shift that many investors...

Alumis (ALMS) is back in focus after releasing new Phase 3 ONWARD1 and ONWARD2 data on envudeucitinib for moderate to severe plaque psoriasis, alongside plans for a U.S. FDA New Drug Application. See our latest analysis for Alumis. The latest Phase 3 psoriasis data arrives after a sharp run up in Alumis’s 90 day share price return of 181.23%, while the year to date share price return of 160.97% and 1 year total shareholder return of 132.54% point to strong momentum even with a 13.12% 30 day...

Why jet fuel and geopolitics suddenly matter more for Southwest Airlines (LUV) The sharp jump in jet fuel costs following the escalation of military operations involving Iran and the closure of the Strait of Hormuz has put Southwest Airlines (LUV) squarely in focus for many investors. Southwest ended its fuel hedging program in early 2025, so the airline now absorbs spot fuel prices directly at a time when energy markets are under pressure from geopolitical risk. See our latest analysis for...

Avery Dennison recently reported advances in its RFID and intelligent labeling technologies, aiming to better support global supply chains across multiple industries. This focus on more capable identification solutions underscores how the company is deepening its role in digitizing inventory tracking and materials management worldwide. Next, we’ll explore how Avery Dennison’s enhanced RFID capabilities could influence its investment narrative around intelligent label adoption and...

Piper Sandler analyst Stephen Scouten recently upgraded FB Financial to a buy rating, while keeping his existing US$65 price target unchanged. The upgrade comes from an analyst with a year-long track record of relatively strong success and average returns, which may carry weight with investors assessing FB Financial’s outlook. We’ll now examine how this vote of confidence from a well-regarded analyst interacts with FB Financial’s existing investment narrative and assumptions. Invest in the...

Market context: ADP National Employment Report and what it means for Automatic Data Processing (ADP) The latest ADP National Employment Report showed private sector employment rising by 62,000 jobs in March, with hiring concentrated in areas such as health care and pay gains for both job-stayers and job-changers. Because this report is produced by Automatic Data Processing (ADP), investors often watch it as a real-time read on payroll activity and broader demand for the company’s human...

In late March 2026, G-III Apparel Group reported FY 2025 Q4 results that fell short of EPS and revenue expectations, posting a US$31.9 million net loss largely tied to a US$17.5 million bad‑debt charge from the Saks bankruptcy and the earlier loss of PVH‑licensed revenue. The bad‑debt exposure to Saks had not been disclosed on the prior earnings call, creating a sharp contrast with management’s earlier optimism and raising questions about earnings visibility and communication. We’ll now...

STAG Industrial (STAG) has been drawing attention after recent share performance data showed a 1 day return of 0.94% and a past month return of 4.07% decline, prompting fresh questions about the industrial REIT’s valuation. See our latest analysis for STAG Industrial. At a share price of US$36.55, STAG Industrial’s recent 1 day share price return of 0.94% follows a 30 day share price decline of 4.07%, while its 1 year total shareholder return of 15.90% contrasts with a mildly negative year to...

Recent performance snapshot First Mid Bancshares (FMBH) has attracted attention after a period of steady share price moves, with the stock up around 4% over the past month and about 6% in the past 3 months. See our latest analysis for First Mid Bancshares. The share price has climbed to $41.65, and that recent strength, including a 7.82% year to date share price return and a 35.50% 1 year total shareholder return, suggests momentum has been building rather than fading. If you are assessing...

Revolution Medicines (RVMD) has begun treating patients in RASolute 303, a global Phase 3 trial of its RAS inhibitor daraxonrasib in previously untreated metastatic pancreatic ductal adenocarcinoma, spotlighting a key late stage pipeline milestone. See our latest analysis for Revolution Medicines. That trial milestone comes after a strong run in the stock, with a 90 day share price return of 26.54% and a one year total shareholder return of 216.48%, pointing to strong momentum around the...

Precigen, Inc. has reported full-year 2025 results, with revenue rising to US$9.68 million from US$3.93 million, while net loss widened to US$250.64 million and basic loss per share from continuing operations increased to US$1.37 from US$0.47, ahead of a recent virtual fireside chat with H.C. Wainwright. The combination of sharply higher revenue and a very large year-on-year increase in net loss gives investors new data on how Precigen’s growth efforts are affecting its financial profile. We...

Nomad Foods stock triggered article Nomad Foods (NOMD) has drawn investor attention after a prolonged share price slump, with the stock showing negative returns over the past year and past 3 months. This performance has prompted a closer look at its current fundamentals. See our latest analysis for Nomad Foods. With the latest share price at $9.58, the stock’s 30 day share price return of 6.63% and 90 day share price return of 20.23% point to fading momentum. At the same time, the 1 year...

Event driven snapshot of CVB Financial CVB Financial (CVBF) has recently drawn attention after a period of solid share performance, with the stock showing positive returns over the past week, month, past 3 months, and year to date. See our latest analysis for CVB Financial. The recent positive 7 day and 30 day share price returns, alongside a 1 year total shareholder return of 21.55% and 3 year total shareholder return of 38.61%, suggest momentum has been building around CVB Financial at a...

Fastenal has begun building a new Southeast U.S. regional operations and logistics center in Carrollton, Georgia, with groundbreaking held on March 24 and opening targeted for spring 2027, replacing its current regional distribution center with a much larger, expandable facility. The project will use next-generation warehouse technologies to increase storage capacity and speed order picking, potentially strengthening Fastenal’s ability to keep more products in stock and improve customer...

In March 2026, NetApp announced alliances with Elastio and Commvault to embed deeper ransomware detection, immutable snapshots, and automated recovery workflows into its data platform, aiming to strengthen enterprise cyber resilience across on‑premises and cloud environments. This integrated, layered defense highlights how NetApp is positioning its storage portfolio at the core of customers’ security, compliance, and recovery architectures in an AI- and data-intensive world. Next, we’ll...

Reports that the US may apply tariffs of up to 100% on certain imported branded drugs have put regulatory risk front and center for Bristol-Myers Squibb (BMY), prompting investors to reassess the stock. See our latest analysis for Bristol-Myers Squibb. After the tariff headlines and the recent ex dividend adjustment, Bristol Myers Squibb’s 1 day share price return of 3.45% contrasts with a 90 day share price return of 12.33% and a 1 year total shareholder return of 13.16%. This suggests...

Roper Technologies (ROP) has refreshed its capital structure with a new five year US$3.5b unsecured revolving credit facility, replacing its prior arrangement and positioning the business with flexible funding capacity. See our latest analysis for Roper Technologies. Despite the refreshed credit facility and ongoing acquisitions, recent market sentiment has been cautious, with a 30 day share price return showing a 2.62% decline and a 90 day share price return showing a 17.09% decline, while...